What we have learned and where do we go from here?
Santa Monica, CA – January 5th, 2016 — Howard Leonhardt, founder of BioLeonhardt and Leonhardt Ventures, will be presenting his team’s experience with stem cell based therapies for repairing damaged organs. The 2016 Academy of Regenerative Practices Winter Conference and Scientific Seminar will be Feb. 5th to 7th held at the Marriott Renaissance Fort Lauderdale-Plantation Hotel, 1230 South Pine Island Rd.,Plantation, FL 33324 -to register to attend click here – https://regenerativeacademy.com/conference
Leonhardt Ventures since 1982 has been involved with developing and bringing to market regenerative medtech and biotech therapies. In 1985 prompted by the publication of Dr. Robert O. Becker’s book The Body Electric they began experimentation to harness the power of bioelectric stimulation to direct regeneration and healing, later joined by Dr. Jorge Genovese. In 1988 Dr. Race Kao a Leonhardt research collaborator working with Dr. George Magovern completed the first muscle stem cell repair of damaged hearts in large animals and published the results the following year in The Physiologist. In 1994 working with Dr. Stuart Williams they began cell sodding stent grafts for aortic aneurysm and heart valve repair. In 1999 working with Wendell King they completed the first successful cases of biological pacemaker implantation (BioPace). May 2001 Leonhardt led the team that completed the first-in-man non-surgical repair of a damaged heart with muscle stem cells in Rotterdam, The Netherlands with Dr. Doris Taylor, Dr. Patrick Serruys, Dr. Pieter Smits, Dr. Warren Sherman and Dr. Kumar Ravi. Since that time Leonhardt Ventures has raised and put to work over $145 million invested in over 15 regenerative medtech/biotech startups that it has founded. The lions share of this funding and research has focused on regenerating damaged hearts. A current translational heart regeneration study is being launched with Dr. Eric Duckers in Europe. Spin outs from this original core technology now focus regenerating eyes, brains, breast tissue, limbs, arteries, heart valves, aortas, dental gums, lungs, joints, pancreas and skin – see www.leonhardtventures.com This full portfolio was presented last month at the World Stem Cell Summit – click here for links to each spin out > http://www.calstockexchange.com/bioleonhardt-myostim-to-present-at-world-stem-cell-summit-2015-atlanta-dec-12th/
Leonhardt Ventures and its associated innovation startup accelerator is led by a team of over 70 medtech/biotech industry veterans – http://calxstars.com/team-cal-x/ and 35 world opinion leader scientific advisory board members – http://calxstars.com/scientific-advisory-board/ ; The team has led numerous products from concept to market and clinical leadership positions since its founding. In the 1980’s they patented and pioneered predictably compliant cardiovascular balloon technologies POLYCATH TM, radiation delivery catheters, electrical stimulation for limb treatments and an artificial lung. In the 1990’s they developed the first commercially successful stent graft TALENT TM , the first percutaneous heart valve, first stem cell micro needle delivery catheters PROCELL TM and the first biological pacemaker made entirely of living cells BIOPACE TM. Since 2000 they have focused on stem cell based regenerative therapies supported by micro pumps, sensors, stimulators and personalized precision medicine. In 2001 they introduced the first cardiovascular genetic test onto the U.S. market, the Pla2 test, for determining the genetic risk for heart attacks helping to launch the era of precision medicine.
Leonhardt has over 200 issued U.S. patents claims and about 100 additional claims pending or in process – http://patents.justia.com/patent/8308708 including a pioneering patent for utilizing a specific bioelectrical signal to direct stem cells, via SDF-1, to any organ location stimulated and controlling their proliferation and differentiation – https://docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US20050171578.pdf
The company’s flagship early stage development is a Whole Body Regeneration Chamber being developed by BioLeonhardt that pulls together into one unit all the separate organ regeneration and healing technologies designed with the goal to extend life by 30 years.
SOURCE Leonhardt Ventures